Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Brune

Showing results (41-50 of 309) with videos related to

Pageof 31
Sort By:
Clinical and Experimental Rheumatology|November 7, 2001
Pharmacokinetic and pharmacodynamic aspects of the ideal COX-2 inhibitor: a pharmacologist's perspectiveK Brune, A Neubert
Experimental Cell Research|February 1, 1980
Carbocyanine dyes stain the sarcoplasmic reticulum of beating heart cellsJ Habicht, K Brune
The Journal of Pharmacy and Pharmacology|November 1, 1983
Inhibition of prostaglandin E2 release by salicylates, benzoates and phenols: a quantitative structure-activity studyJ Habicht, K Brune
Der Orthopade|December 16, 2006
[Pain therapy with antipyretic analgesics]B Hinz, K Brune
Deutsche Medizinische Wochenschrift (1946)|April 22, 2010
[Drug safety problems in association with the use of opioid containing patches for the management of pain]T Stammschulte, K Brune
Fortschritte Der Medizin|November 20, 1988
[Bioequivalence of generic drugs: sense and nonsense]K Brune, K Dietzel
Der Internist|July 1, 1986
[Pharmacology of peripherally acting analgesics]K Brune, G Kobal
Agents and Actions|February 1, 1988
Detection of autoimmunoreactive antibodies against cartilage cell surface proteins in the blood of rheumatic patientsJ Mollenhauer, K Brune
Agents and Actions|June 1, 1983
Non-acidic pyrazoles: inhibition of prostaglandin production, carrageenan oedema and yeast feverK Brune, H Alpermann
Clinical Pharmacology and Therapeutics|May 8, 2009
Are myocardial infarctions and death in healthy individuals associated with the use of cyclooxygenase inhibitors?B Renner, K Brune
Pageof 31

Showing results (41-50 of 309) with videos related to

Sort By:
Pageof 31
Clinical and Experimental Rheumatology|November 7, 2001
Pharmacokinetic and pharmacodynamic aspects of the ideal COX-2 inhibitor: a pharmacologist's perspectiveK Brune, A Neubert
Experimental Cell Research|February 1, 1980
Carbocyanine dyes stain the sarcoplasmic reticulum of beating heart cellsJ Habicht, K Brune
The Journal of Pharmacy and Pharmacology|November 1, 1983
Inhibition of prostaglandin E2 release by salicylates, benzoates and phenols: a quantitative structure-activity studyJ Habicht, K Brune
Der Orthopade|December 16, 2006
[Pain therapy with antipyretic analgesics]B Hinz, K Brune
Deutsche Medizinische Wochenschrift (1946)|April 22, 2010
[Drug safety problems in association with the use of opioid containing patches for the management of pain]T Stammschulte, K Brune
Fortschritte Der Medizin|November 20, 1988
[Bioequivalence of generic drugs: sense and nonsense]K Brune, K Dietzel
Der Internist|July 1, 1986
[Pharmacology of peripherally acting analgesics]K Brune, G Kobal
Agents and Actions|February 1, 1988
Detection of autoimmunoreactive antibodies against cartilage cell surface proteins in the blood of rheumatic patientsJ Mollenhauer, K Brune
Agents and Actions|June 1, 1983
Non-acidic pyrazoles: inhibition of prostaglandin production, carrageenan oedema and yeast feverK Brune, H Alpermann
Clinical Pharmacology and Therapeutics|May 8, 2009
Are myocardial infarctions and death in healthy individuals associated with the use of cyclooxygenase inhibitors?B Renner, K Brune
Pageof 31